The price of 6 items of Choline alfoscerate is cut

despite the decision to limit reimbursement

Completed negotiations for PVA type Da including Gliatamin

The government recognized benefits only for dementia in 2020 but is on probation

Last year, 10 items with the same ingredients were reduced in price through the PVA system

Despite the government's decision to limit reimbursement, the brain function-improving drug Choline Alfoscerate continues to come out with price cuts due to increased usage.

 

It was found that 6 Choline Alfoscerate items were included in the PVA type Da negotiations this year as well.

 

According to the industry on the 7th, negotiations were conducted as Gliatamin drugs such as Gliatamin were included in the Type Da target this year.

 

Choline Alfoscerate ingredient items that have been negotiated are Ahn-gook Kanoa Soft Cap., Korea Prime Pharmaceuticals Gria Soft, Daewoong Bio Gliatamine Soft Cap, and Gliatamine.

 

They negotiated for the number of claims in 2022 to exceed the PVA Type Da standard.

 

Criteria for each type is when the claim amount for the calculated drug increased by 60% or more from the previous year's claim amount or increased by 10% or more and the increase amount was 5 billion won or more.

 

In the case of Ahn-gook Kanoa, the number of outpatient prescriptions based on UBIST was 6.8 billion won in 2022, up 68% from the previous year, Korea Prime Pharm.

 

Gria’s sales were 29 billion won, up 17% from the previous year, and Daewoong Bio Gliatamin’s sales increased by 5% to 115.6 billion won.

 

Kanoa and Gliatamine had their drug prices reduced last year as PVA.

 

The use of Choline alfoscerate continues to increase despite the decision to reduce benefits in 2020.

 

In September 2020, the government decided to allow reimbursement for Choline Alfoscerate drugs only for dementia patients and apply selective reimbursement by applying 80% patient copayment for the remaining indications.

 

Specifically, 'secondary symptoms and degenerative or degenerative brain organic mental syndrome due to cerebrovascular defects: memory loss and confusion, disorientation due to decreased motivation and spontaneity, decreased motivation and spontaneity, and decreased concentration' in patients diagnosed with dementia It was agreed that reimbursement would be recognized for administration and 80% patient copayment would be applied to prescriptions other than the accreditation standards.

 

The implementation has been suspended as related pharmaceutical companies filed lawsuits for suspension of execution and cancellation of benefit reduction.

 

Since then, even the indications have been reduced in the process of clinical re-evaluation planning, but the amount of prescriptions in the field has not decreased.

 

Even last year, the Choline Alfoscerate preparation Chongkundang Gliatirin Soft Cap.

 

10 items, including original drugs, were included in the PVA target, and the drug price was reduced.